Development of a novel tobramycin dependent riboswitch
Abstract
We herein report the selection and characterization of a new riboswitch dependent on the aminoglycoside tobramycin. Its dynamic range rivals even the tetracycline dependent riboswitch to be the current best performing, synthetic riboswitch that controls translation initiation. The riboswitch was selected with RNA Capture-SELEX, a method that not only selects for binding but also for structural changes in aptamers on binding. This study demonstrates how this method can fundamentally reduce the labour required for the de novo identification of synthetic riboswitches. The initially selected riboswitch candidate harbours two distinct tobramycin binding sites with KDs of 1.1 nM and 2.4 μM, respectively, and can distinguish between tobramycin and the closely related compounds kanamycin A and B. Using detailed genetic and biochemical analyses and 1H NMR spectroscopy, the proposed secondary structure of the riboswitch was verified and the tobramycin binding sites were characterized. The two binding sites were found to be essentially non-overlapping, allowing for a separate investigation of their contribution to the activity of the riboswitch. We thereby found that only the high-affinity binding site was responsible for regulatory activity, which allowed us to engineer a riboswitch from only this site with a minimal sequence size of 33 nt and outstanding performance.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 04, 2023
- Source ID
- 10.1093/nar/gkad767
Entities
People
- Adrien Boussebayle
- Beatrix Suess
- Cristina Bofill-bosch
- Daniel Kelvin
- Elke Duchardt-Ferner
- Eric Bräuchle
- Hans Marx
- Jens Wöhnert
- Leon Kraus
- Lisa-marie Maurer
- Simon Fürbacher
Organizations
- Aarhus University
- German Research Foundation
- Office of Naval Research
- Technical University of Darmstadt